新华制药：沙库巴曲缬沙坦钠片取得药品注册证书

Company Overview - Xinhua Pharmaceutical (SZ 000756) announced the approval of Sacubitril/Valsartan Sodium Tablets by the National Medical Products Administration [1] - As of the announcement, Xinhua Pharmaceutical has a market capitalization of 11.4 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of Xinhua Pharmaceutical is as follows: - Chemical drug formulation manufacturing accounts for 48.1% - Chemical raw material manufacturing accounts for 32.32% - Pharmaceutical intermediates and others account for 19.59% [1]